Is radium‑223 a universal drug of bone metastasis in castration‑resistant prostate cancer?
03/2018
MUDr. Jana Katolická, Ph.D.1; MUDr. Petr Filipenský, Ph.D.2
1) Onkologicko-chirurgické oddělení, FN u svaté Anny, Brno
2) Urologické oddělení, FN u svaté Anny, Brno
SUMMARY
Bone metastases in prostate cancer are a major cause of pain and bone complications. Radium-223 treatment of patients with bone metastasis in castration-resistant prostate cancer proved to be beneficial in prolonging overall survival. Administration of 5-6 doses of radium-223 compared to 1-4 doses is associated with a significantly longer overall survival. The most common haematological adverse event induced treatment is anemia and thrombocytopenia.
KEY WORDS
metastatic castration resistant prostate cancer, bone metastasis, radium-223
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...